



Biomega Unveils Whitepaper on Role of Salmon Peptides in Supporting Cardiovascular Health

There is increasing science-backed evidence available that shows how functional food ingredients and supplements can reduce the risk of cardiovascular disease. To find out more, you can download our whitepaper [here](#).

15.06.2020

Download the whitepaper by filling out your contact details [here](#).

Biomega Group ('Biomega'), a leading biosciences company producing high-quality ingredients for the health and nutrition sectors, has released a new whitepaper discussing the positive contribution salmon peptides could have on minimising the risk factors associated with cardiovascular disease.

Each year, cardiovascular disease ('CVD') accounts for 3.9 million deaths in Europe and is the primary cause of death in the region according to the European Heart Network. With dietary factors the largest contribution to the risk of CVD mortality, maintaining a healthy diet and active lifestyle is one of the best ways to combat two of the greatest medical risks associated with the disease; high systolic blood pressure and bad cholesterol.

Bjorn Liaset, Director of R&D at Biomega said: "There is increasing science-backed evidence available that shows how functional food ingredients and supplements can help reduce the risk of CVD and coronary heart disease by lowering what's known as the 'bad' low-density lipoprotein ('LDL') cholesterol, while simultaneously improving the 'good' high-density lipoprotein ('HDL') cholesterol.

"Our whitepaper explores how niacin, which is found at high levels in Biomega salmon peptides, can elevate good cholesterol to promote general heart wellness in humans. In addition, we also discuss how the anti-atherosclerotic properties of salmon peptides can aid in cardiovascular protection."

Entitled, 'Understanding Salmon Peptides and Cardiovascular Health', the whitepaper is the first in a series of releases from Biomega explaining the benefits of salmon peptides in human and animal health. The whitepaper, which is available to download for free, can be accessed by emailing hello@phdmarketing.co.uk.

To download the whitepaper, please fill out your contact details [here](#). For more information on Biomega, please visit <https://biomegagroup.com/>.

About Biomega Group

The Biomega Group aspires to become the leading partner for innovative high-quality ingredients to the health & nutrition industry. Biomega's business model is fully sustainable and uses proprietary biotech to transform high quality raw material into premium food and feed ingredients. In its modern food grade biorefinery in Norway, Biomega produces hydrolyzed salmon proteins (salmon peptides), salmon meal and salmon oil. Biomega invests continuously in R&D to ensure best-in-class technology and respond to customers' needs, including traceability and sustainability. The Biomega Group is a portfolio company of AMERRA Capital Management.

About AMERRA Capital Management

AMERRA is an independent asset management firm, providing strategic capital to upstream and midstream food and agri-businesses in Europe and the Americas. AMERRA brings unique value to its



portfolio companies through its extensive network, in depth knowhow and a sole focus on the field. Throughout its dedicated strategies of private credit, special situations, and private equity, AMERRA adheres to best Environmental & Social practices and belongs to the United Nations Environment Program – Finance Initiative. Backed by long-term institutional capital with more than US\$ 1.7bn in assets under management, AMERRA has invested over \$5.2 billion since its inception in 2009. For more information about AMERRA please visit www.amerracapital.com.

Contact

David Gould
Head of Investor Relations and Capital Markets
AMERRA Capital Management
+1 (212) 710-8023
dgould@amerracapital.com